Baudax Bio Inc. (BXRX): Key fundamentals of BXRX


Baudax Bio Inc. (NASDAQ:BXRX) changes shares on Friday trading session, with a change of -6.42% or -$0.26 shares. The trading starts at $4.11 and closed at $4.05 throughout the day. The trading session low price was $3.79 and day high was $4.19 on Friday, June 19. After the session, the Healthcare sector daily volume shifted to 0.62 million while its average volume is 988.41K. In other hand, the BXRX market cap reached to $71.21M. While, its current target price is $3.79 according to WSJ.

Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is up 6.46% and down -6.65% for month. Its quarterly performance was -10.82% below, while its half year performance is down -30.59%. BXRX performance fall -45.23% for year-to-date. Current recommendation for Baudax Bio Inc. is 1.70.

Earnings per share or EPS is an important financial measure, which defines the profitability of a company. BXRX EPS (TTM) for 12-month is -7.05. EPS for this year is 57.10%, while for the next year its value is -1.95. Its EPS Q/Q reached -743.90%.

Let’s take a look on the analyst recommendations on BXRX for the current month and previous month. For the current month, 3 of 3 analysts recommend stock as Buy while 0 as Sell, 0 as overweight, 0 as underweight and 0 as Hold. As compared with the previous month ratings, 0 analysts participate in stock recommendation. Out of 0, 0 rated it sell, 0 rated it as Buy and 0 as Hold Ratings. On the other hand, target price ranges from $13.00-$14.00. Average target price for BXRX was reached at $13.67.

North Run Capital LP, Corsair Capital Management, L.P. and Stonepine Capital Management, LLC are the top three holders in Baudax Bio Inc. (BXRX) stock. On Mar 30, 2020, North Run Capital LP has 1.15 million shares which valued 2.86 million. On Mar 30, 2020, Corsair Capital Management, L.P. owned 0.88 million shares which valued at 2.18 million. On Mar 30, 2020, Stonepine Capital Management, LLC has a total of 0.61 million shares which valued at 1.51 million. In the end, Stonepine Capital Management, LLC have 3.47% shares outstanding of Baudax Bio Inc. (BXRX) on Mar 30, 2020. The insider ownership moved to 4.00% and institutional holding shifted to 58.30%.

The company posted an EPS (TTM) of -7.05. According to the most recent quarter report on (Jun 2020), 3 analysts estimated an average EPS of -0.65. Analyst Estimated EPS for BXRX published in the report was -1.03–0.44 during the same period.

A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for BXRX fall -29.02% for period of 200 days. SMA for 50 days was 10.03% which is showing green signal, while SMA-20 was -6.14%. The moving average value for Baudax Bio Inc. (BXRX) is 5.3055 and 3.8309 for 200 and 50 days respectively.

Let’s take a look on the insider transactions, in which multiple shareholders are showing interest in BXRX stock. On Mar 26, CHURCHILL WINSTON J, Director, bought 6,500 trading shares at the cost of $2.28, which valued at 14820.0. On Mar 26, CHURCHILL WINSTON J, Director, bought 25,000 shares at the cost of $2.44, with total shares of 52,782. On Mar 26, Weisman Wayne, Director, bought 10,000 shares at the cost of 2.29. After this transaction, Weisman Wayne total shares reached to 40,582 which valued at 22900.0.